Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

1,618 public trials 340 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Completed

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

NCT05597085

Conditions
Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +23 more
Locations
  • Fortis Memorial Research Institute Gurugram, Haryana, India
  • Malabar Cancer Center Thalassery, Kerala, India
  • Rajiv Gandhi Cancer Institute and Research Centre New Delhi, National Capital Territory of Delhi, India
  • Indo-American Cancer & Research Centre Hyderabad, Telangana, India
View Trial Details
Completed

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

NCT03031483

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Medical University of Vienna Vienna, Austria
  • A.O. Spedali Civili di Brescia Brescia, Italy
  • Azienda Ospedaliera Papardo Messina, Italy
  • IRCCS Ospedale San Raffaele Milan, Italy
View Trial Details
Completed

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Oncology Specialties: Clearview Cancer Institute Huntsville, Alabama, United States
  • University of Arizona Tucson, Arizona, United States
  • Central Arkansas Radiation Therapy Institute Little Rock, Arkansas, United States
  • Desert Hematology Rancho Mirage, California, United States
View all 39 locations
View Trial Details
Completed

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03484702

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Local Institution - 101 Vienna, Austria
  • Local Institution - 351 Ghent, Belgium
  • Local Institution - 551 Helsinki, Finland
  • Local Institution - 202 Lille, France
View all 20 locations
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details

Related conditions